NCT04191499 2026-03-17
INAVO120
Hoffmann-La Roche
Phase 2/3 Active not recruiting
Clinical Trials
5 trialsNCT06506955 2026-03-11
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
NCT02692755 2021-09-28
PALINA
Georgetown University
Phase 2/3 Completed
NCT04753177 2021-02-15
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
Phase 2/3 Unknown
NCT02116803 2018-03-01
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Novartis
Phase 2/3 Completed